Rental investor numbers fall for only third time in 25 years, ATO data shows
The other occasions coincided with the 2008 global financial crisis and the COVID-19 pandemic reaching Australian shores.
There were 7,081 fewer rental investors in 2022-23, equating to a modest 0.3 per cent reduction.
However, it was a noted reversal to the general trend in records going back to 1999-2000, when an average year saw the number of investors declaring rental income increase by about 47,000.
While the overall number of investors shrank, the decline was concentrated among those with multiple investment properties.
An ABC analysis of different groups of investors showed a general trend that the more rentals a group owned, the more the size of that group shrank between 2021-22 and 2022-23.
The number of investors declaring income from only one rental actually grew by 2,337, while the number with two or more fell.
Investor groups blame interest rates, less investor-friendly tax and policy settings, and increased tenants' rights for the drop-off of investors.
Landlord Glenn Langdon agreed with the assessment — similar factors had led to his decision to sell his only Victorian rental, in Greenvale, last week.
He was using the money to buy a third rental in Queensland, where he said taxes were lower and there were fewer demands on investors.
"There just seems to be constantly more and more cost to own a rental property in Victoria than in other states," he said.
A ban on no-fault evictions, hikes in land taxes for investors, and increased renter rights had all contributed to his decision to sell.
"There's no protection for the landlord, I feel," said Mr Langdon.
Eliza Owen, head of research for property data firm Cotality, told ABC News it might seem surprising investor numbers have fallen when residential real estate was "so often heralded as a safe investment".
It became less surprising when you considered that the 2022-23 financial year was characterised by falling home values and rapidly rising interest rates, she said.
"Between June 2022 and 2023, the average outstanding investor mortgage rate rose from 3.88 per cent to 6.6 per cent, increasing the repayment on a $500,000 loan by $830 per month.
"By comparison, median monthly rent values in Australia increased by $316."
Ms Owen said there were advantages and disadvantages to a smaller cohort of investors — one being that it might free up more stock for home owners to buy.
However, it was unclear if this had come to fruition, with no reliable home ownership rate data since 2021.
Australian Bureau of Statistics (ABS) lending data showed investors made up between 25 and 30 per cent of home borrowing between late 2019 and late 2021, before beginning a slow recovery to make up around 38 per cent of borrowing in the March quarter of this year, suggesting investors were returning to the market.
Ms Owen said it was hard to say whether the investor cohort has grown since 2022-2023 but, with housing values back to record highs and interest rates stabilising and now beginning to fall, it was possible investor numbers would grow again.
Property Investors Council of Australia chair Ben Kingsley said changes in the investor cohort were heavily influenced by government policy and interest rates.
He pointed to 1999, when the Howard government introduced the 50 per cent capital gains discount — triggering a period of investors buying in (which was also a period of rising house prices) followed by a blip around the global financial crisis, which followed a period of high interest rates, and then renewed growth from low interest rates after the GFC.
Then, in 2017, Mr Kingsley pointed to the ban on travel and depreciation claims on existing properties, followed by a raft of reforms to lending rules and state tenancy laws over subsequent years, which appeared to dampen investor interest.
He said over the five years to mid-2023, the average annual increase in investor numbers sat at around 10,600 — well below the 53,000-64,000 experienced during the three five-year periods preceding it.
"Add these numbers to the exodus we are seeing in Victoria, and it's blatantly clear we have a housing supply problem, partly because investors running their private rentals are tapping out," he said.
While the ATO data showed slowing but still positive growth in Victorian investors, more recent rental bond data indicated an investor sell-off, with the state losing more than 24,000 rentals during 2024 — or 3.6 per cent of the state's entire rental stock, which has proven a boon for first home buyers trying to get into the market.
Mr Kingsley said property building would suffer without willing investor money.
However, building investment is difficult to track.
Cotality's Ms Owen said it was "quite possible" subdued investor activity has resulted in less construction activity than otherwise.
"CBA has reported in a previous economic note that about half of off-the-plan demand in new apartment buildings comes from the investor cohort," she said.
Richard Temlett, national executive director of Research at Charter Keck Cramer, advises developers and government on housing policy.
He said he had never come across reliable data that showed whether domestic investment in new-builds had fallen, but investment figures from NAB showed foreign cash going into building had dropped since 2018.
"Foreign investors have a very bad wrap, people keep thinking they are buying established dwellings, driving up property prices, stealing properties from locals," Mr Temlett observed.
"That's not the case at all, especially with the legislation that mainly says it has to be for new supply of dwellings.
Urban Development Institute of Australia (UDIA) chief operating officer Peter Sherrie said flagging investor demand, driven by higher taxes and construction costs, had resulted in many approved medium density and high-rise developments around the country sitting unstarted.
UDIA represents the property development industry, with more than 2,500 member companies.
"When the feasibilities aren't working, the developers aren't able to achieve their construction funding, and the project doesn't start," he said.
While investors could once increase rent to make investments work, that option seemed to have dried up.
"It's reaching that ceiling now … tenants just cannot afford to pay more, it's just beyond their capacity," Mr Sherrie said.
He said building continued at greenfield developments, which had a lower entry cost and greater capital gain potential, the build-to-rent market, and developments that sold directly to home owners, where apartments were generally larger, finished to a higher standard, and more expensive.
Rayna Fahey, who is director of advocacy at pro-land tax non-profit research institute Prosper, said a fall in investors declaring rental income did not necessarily mean rentals were sold, and may mean investors simply left the property empty, satisfied with waiting for capital gain.
"Our tax system rules so heavily rewards speculation over production, speculation really distorts the property market," Ms Fahey said.
If investors did sell, she said it would likely be to a home owner, who would live in the home, or possibly to another investor who would rent it out.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
29 minutes ago
- News.com.au
Australian retail spending weak despite RBA rate cut
Australians are spending a little more at the shops after the Reserve Bank of Australia cut interest rates in May, but it was not the boost to spending that experts were hoping for. Retail sales jumped 0.2 per cent in May following a disappointing April when sales fell by 0.1 per cent despite two long weekends in the period. Oxford Economics Australia head of economic research and global trade Harry Murphy Cruise said households remained pessimistic and it was weighing on sales. 'For households, the uncertainty of global events and the ghosts of inflation past are trumping the good news in the labour market,' he said. 'Unemployment remains remarkably low, with soaring job vacancies suggesting workers can remain confident that good news will continue. 'But the shadow of tariffs, the slowdown in China, and years of price rises eroding real disposable incomes are keeping households' wallets firmly closed.' Mr Murphy Cruise said Wednesday's results showed households needed more convincing via rate cuts before they lifted spending. 'Today's data is another notch in the column to cut rates when the RBA meets next week,' he said. ABS head of business statistics Robert Ewing said spending remained weak, with the jump on the back of clothing purchases. 'Retail spending was otherwise restrained this month, with a drop in food-related spending and flat results across household goods,' he said. Clothing, footwear and personal accessory retailing rallied 2.9 per cent and department stores were up 2.6 per cent, but they were the only industries to rise, although both were off the back of large falls in April. 'Clothing retailers and department stores were boosted by people buying winter clothes, having held off on those purchases with the warmer-than-usual weather last month,' Mr Ewing said. While there was a bounce in clothing retailing, food-related spending fell for the first time this year. Food retailing went backwards 0.4 per cent for the month, while spending in cafes, restaurants and takeaway food services came in flat. The weaker-than-expected results came as experts said retail growth would be about 0.5 per cent on the back of a rate cut in May.

News.com.au
an hour ago
- News.com.au
Top 10 at 11: ASX jumps on open as copper and battery metals rally
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Resources drive early gains The ASX 200 has jumped 0.42% in the first half hour of trading, with 9 of 11 sectors making gains as of about 10:30 am AEST. The materials sector is leading the charge, building on momentum generated by a rally in lithium and battery metal stocks and a 5.9% jump in James Hardie (ASX:JHX) shares. The construction materials company completed its acquisition of NYSE-listed outdoor living business AZEK today, adding to its extensive portfolio of exterior design brands. Lithium, rare earth and copper stocks are making the biggest moves this morning, including several of the stocks on our small cap winners list… WINNERS Code Name Last % Change Volume Market Cap PKO Peako Limited 0.003 50% 120000 $2,975,484 EEL Enrg Elements Ltd 0.002 33% 792525 $4,880,668 IS3 I Synergy Group Ltd 0.002 33% 620409 $2,253,285 SRN Surefire Rescs NL 0.002 33% 1500000 $3,729,668 LAT Latitude 66 Limited 0.029 26% 10932 $3,298,216 ADG Adelong Gold Limited 0.005 25% 60000 $8,274,707 DY6 Dy6Metalsltd 0.145 23% 1246772 $8,749,344 HOR Horseshoe Metals Ltd 0.025 19% 670720 $14,070,141 BCA Black Canyon Limited 0.16 19% 405899 $17,502,844 ID8 Identitii Limited 0.007 17% 15000 $4,668,081 In the news... Horseshoe Metals (ASX:HOR) is preparing to fire up its direct shipping ore operations for the Horseshoe Lights copper-gold project in WA, after getting the greenlight from the DEMIRS. HOR expects to have boots on the ground within the next few weeks, with sales of existing copper stockpiles to begin shortly thereafter. It's perfect timing for the company, with the price of copper soaring more than 26% in the year to date to reach 10-year highs. Latitude 66 (ASX:LAT) is offloading its 17.5% interest in the Greater Duchess joint venture project, triggering a right of first refusal for JV partner Carnaby Resources (ASX:CNB). LAT is looking to sell its interest for $2m, with some conditional payments on the table of up to $4m in cash or ASX-listed shares. If the project is sold within 90 days of the sale and anyone can get their hands on 100% of the project interest, LAT will be $4m richer; if only a partial sale is made in that time, the company will earn 50% of any proceeds above $4m. LAGGARDS Code Name Last % Change Volume Market Cap AOA Ausmon Resorces 0.001 -50% 111800 $2,622,427 VHL Vitasora Health Ltd 0.03 -23% 3864299 $61,504,061 MMR Mec Resources 0.004 -20% 504034 $9,248,829 PIL Peppermint Inv Ltd 0.002 -20% 100000 $5,752,724 C29 C29Metalslimited 0.015 -17% 1772692 $3,135,388 CUS Coppersearchlimited 0.016 -16% 100593 $3,018,941 RDS Redstone Resources 0.003 -14% 150000 $3,619,936 RNX Renegade Exploration 0.0035 -13% 616666 $5,153,454 CPV Clearvue Technologie 0.14 -13% 368291 $42,980,027 NYM Narryermetalslimited 0.031 -11% 101959 $6,161,918

News.com.au
an hour ago
- News.com.au
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
As today's Medadvisor deal attests, underperforming biotech assets are getting a bite or two Next Science shares continue to rally, but the company is still valued at less than Demant's offer price for most of its assets Neurizon enters a key deal with the supplier of its drug candidate for motor neurone disease Inspired by the 50 th anniversary of the original Jaws movie, local and offshore predators are on the hunt for local biotech prey. Today, medication compliance group MedAdvisor (ASX:MDR) said it had entered a binding agreement to sell its Australian ops to the Canadian owned Jonas Software, for a headline $35 million. As we reported yesterday, Medadvisor was the worst performing ASX-listed biotech last financial year, sinking 82%. Yesterday, struggling wound management company Next Science (ASX:NXS) proposed a US$50 million ($75 million) deal to sell most of its assets. The buyer is the Milan based Demetra Holdings (see below). Mayne Pharma (ASX:MYX) is – or was – subject to a $600 million offer from US dermatology group Cosette, but the suitor spat out the arm after due diligence (allegedly) revealed horrors lurking in depths. As with the makers of the epic Jaws movie, we must apologise to the sea's apex predators for besmirching their reputation. Unlike with the six remarkably careless Jaws 1 victims, biotech's metaphorical equivalent is usually most welcome. Medadvisor prefers US focus Coming back to Medadvisor, the company wants to focus on its bigger US business, which provides prescription drug information services to patients via big pharma and chemists. The terms are like the non-binding ones announced on May 9. One quirk is that the deal includes the Medadvisor moniker, but Medadvisor can continue to use that name under a royalty-free arrangement. Still, the company will seek shareholder approval to change its name. While Medadvisor pockets $35 million now, it has dibs on an 'uncapped contingent consideration' based on the divested arm's performance. On current trends, the company would expect another $7.35 million. Medadvisor intends to use some of the proceeds to discharge a $23.5 million finance facility. The company will use the remainder pending a review of its US operations, which have been hit by a downturn in vaccination rates. This has resulted in the jab makers winding back promotional spend. Next Science investors retain zeal for deal Having pushed up Next Science shares 64% yesterday, investors today added another 9% on the back of the proposal that in effect will see their company disappear. The proposal is subject to the consent of Next Science shareholders at a meeting scheduled on August 14. In framing the friendly deal, Demetra no doubt has chatted to Next Science's 37% shareholder, property tycoon and biotech dabbler Lang Walker. The deal is also subject to an independent expert report. Next Science intends to redistribute to shareholders the estimated US$30 million remaining after winding up costs. With approved products in the US, Next Science operates in wound care and surgical infection control. Demetra supplies bone cement, for fixing orthopaedic implants and the like. Next Science's regally dubbed CEO, Harry Hall IV says that in Demetra's more capacious hands Next Science's products 'will be better positioned to realise their full potential in improving patient care globally'. Next Science listed at $1 in April 2019 in a $35 million IPO and peaked at close to $2 in mid 2021. It's been downhill from there. Meanwhile the ASX circle of life continues, with wound management house Tetratherix (ASX:TTX) listing successfully last Monday. Interestingly, Next Science still bears a market cap of a mere $34 million. Neurizon does 'vet' deal but it's not going to the dogs The developer of a repurposed drug candidate for a form of motor neurone disease, Neurizon Therapeutics (ASX:NUZ) has entered an exclusive global licensing agreement with the New York-listed Elanco Animal Health. The deal doesn't take Neurizon back into veterinary drugs, the company's key remit when it was known as Pharmaust. But Elanco is the exclusive maker of the drug candidate – monepantel – which regulators originally approved as a sheep drench. Monepantel is the active component of NUZ-001, Neurizon's lead therapy for amyotrophic lateral sclerosis (ALS) and other human neurodegenerative diseases. The deal bestows Neurizon with the global rights for Elanco's intellectual property, including extensive non-clinical (animal) and manufacturing data. The agreement also outlines key terms for Elanco's future supply of monepantel, with a formal agreement expected in the current half. Monepantel works by inhibiting the mTOR signalling pathway, which plays a central role in the growth of cancer cells and the degeneration of neurons. mTOR stands for the 'mechanistic Target of Rapamycin', a reference not to a Tolkien novel but a well-known oncology target (rapamycin). Neurizon is participating in Healey ALS, a collaborative MND trial across 70-plus sites in the US. The platform will test several drugs simultaneously, thus increasing patient access and reducing study costs and completion and enrolment times. Neurizon CEO Dr Michael Thurn says the deal should 'dramatically reduce near-term development costs and accelerate development timelines.' The deal involves a nominal up-front payment and back-ended development milestones of US$9.75 million for the initial product. Should sales take off, Neurizon pays sales milestones of up to US$65 million but we'll cross that bridge when we come to it. Emvision's Emu hops to five sites, with one more to come The developer of a portable bedside stroke scanner dubbed Emu, EMvision Medical Devices (ASX:EMV) hopes to sign up its sixth and final site for its pivotal trial pitched at regulatory approval. The company today said five sites – three in the US and two locally – were now 'actively enrolling and scanning patients'. The three US sites are New York's Mt Sinai Hospital, Florida's Mayo Clinic and UT Health Memorial Hermann Texas Medical Centre. The local sites are Royal Melbourne Hospital and Sydney's Liverpool Hospital. The sixth site, at a west coast US clinic, should be announced 'shortly'. Emvision also won assent to start a continuous innovation study for stroke and traumatic brain injury patients, at Newcastle's John Hunter Hospital and Brisbane's Princess Alexandra Hospital. The trial involves enrolling up to 300 suspected stroke victims. Clinicians will assess them in the normal manner along with an Emu scan. The study aims to determine accurately whether a stroke is a blood clot or a bleed. If Emu takes flight, the company plans to seek expedited US approval for an ambulance variant, called First Responder.